Jóri, B.; Falk, M.; Hövel, I.; Weist, P.; Tiemann, M.; Heukamp, L.C.; Griesinger, F.
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Curr. Oncol. 2022, 29, 6628-6634.
https://doi.org/10.3390/curroncol29090520
AMA Style
Jóri B, Falk M, Hövel I, Weist P, Tiemann M, Heukamp LC, Griesinger F.
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Current Oncology. 2022; 29(9):6628-6634.
https://doi.org/10.3390/curroncol29090520
Chicago/Turabian Style
Jóri, Balázs, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp, and Frank Griesinger.
2022. "Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy" Current Oncology 29, no. 9: 6628-6634.
https://doi.org/10.3390/curroncol29090520
APA Style
Jóri, B., Falk, M., Hövel, I., Weist, P., Tiemann, M., Heukamp, L. C., & Griesinger, F.
(2022). Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Current Oncology, 29(9), 6628-6634.
https://doi.org/10.3390/curroncol29090520